Over the recent years, leading companies like Ranbaxy, Sun Pharma and Wockhardt have faced regulatory action by the USFDA over quality issues at their domestic facilities.
Monday, 14 July 2014
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment